克唑替尼治疗EML4-ALK重排阳性患者的临床疗效

目的探讨EML4-ALK融合基因阳性与阴性非小细胞肺癌患者在应用不同治疗方案后的临床疗效。方法对有自主意愿
进行EML4-ALK基因检测的21例ALK阳性、50例ALK阴性与75例未行ALK检测的非小细胞肺癌患者，对3组患者给予不同
的治疗方法，并对疗效、无疾病生存期及不良反应做出统计学分析。结果对于EML4-ALK阳性患者，应用克唑替尼后的PFS
明显延长，其客观缓解率为61.9%，明显高于应用化疗药物之后的客观缓解率。对比与EML4-ALK阴性及未测组的二线治疗方
案，其客观缓解率及疾病控制率也有显著统计学差异。结论克唑替尼对EML4-ALK阳性患者具有更好的疗效，EML4-ALK基
因重排与否对化疗药物并无影响。

Therapeutic effects of crizotinib in EML4-ALK-positive patients with non-small-cell lung cancer

Objective To evaluate the therapeutic effects of different therapeutic regimens for non-small-cell lung cancer
(NSCLC) with or without EML4-ALK rearrangement. Methods Twenty-one ALK-positive and 50 ALK-negative NSCLC
patients who received voluntarily EML4-ALK testing and 75 NSCLC patients without AL testing were enrolled in this study.
The 3 groups of patients received different treatments, and the therapeutic effects, progression-free survival (PFS), and
treatment-related adverse events were analyzed. Result Crizotinib treatment obviously prolonged the PFS in
EML4-ALK-positive patients with an objective response rate (OOR) of 61.9% and a median response duration of 16 months,
which were significantly better than those in with ALK-negative patients and patients without ALK testing who received
different second-line therapies. Conclusion Crizotinib is superior to platinum-based chemotherapy in NSCLC patients with
ALK rearrangement. ALK rearrangement id not a modifier of the effect of chemotherapy regimens in NSCLC patients.